Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

By | December 30, 2021
New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.